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Abstract
Background: The Palliative Performance Scale (PPS) was first introduced in1996 as a new tool for
measurement of performance status in palliative care. PPS has been used in many countries and has
been translated into other languages.
Methods: This study evaluated the reliability and validity of PPS. A web-based, case scenarios study
with a test-retest format was used to determine reliability. Fifty-three participants were recruited
and randomly divided into two groups, each evaluating 11 cases at two time points. The validity
study was based on the content validation of 15 palliative care experts conducted over telephone
interviews, with discussion on five themes: PPS as clinical assessment tool, the usefulness of PPS,
PPS scores affecting decision making, the problems in using PPS, and the adequacy of PPS
instruction.
Results: The intraclass correlation coefficients for absolute agreement were 0.959 and 0.964 for
Group 1, at Time-1 and Time-2; 0.951 and 0.931 for Group 2, at Time-1 and Time-2 respectively.
Results showed that the participants were consistent in their scoring over the two times, with a
mean Cohen's kappa of 0.67 for Group 1 and 0.71 for Group 2. In the validity study, all experts
agreed that PPS is a valuable clinical assessment tool in palliative care. Many of them have already
incorporated PPS as part of their practice standard.
Conclusion: The results of the reliability study demonstrated that PPS is a reliable tool. The
validity study found that most experts did not feel a need to further modify PPS and, only two
experts requested that some performance status measures be defined more clearly. Areas of PPS
use include prognostication, disease monitoring, care planning, hospital resource allocation, clinical
teaching and research. PPS is also a good communication tool between palliative care workers.
Background
The Palliative Performance Scale (PPS) was first intro-
duced by Anderson and Downing in 1996 as a new tool
for measurement of performance status in palliative care
[1]. Its initial uses in Victoria, British Columbia included
communication, analysis of home nursing care workload,
profiling admissions and discharges to the hospice unit
and prognostication. PPS has been used in many coun-
tries and has been translated into other languages, includ-
ing French, Japanese, German and Thai (from private
correspondence of Downing GM, 2008). In a recent sys-
tematic review on clinical assessment tools for quality of
Published: 4 August 2008
BMC Palliative Care 2008, 7:10 doi:10.1186/1472-684X-7-10
Received: 28 April 2008
Accepted: 4 August 2008
This article is available from: http://www.biomedcentral.com/1472-684X/7/10
© 2008 Ho et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Palliative Care 2008, 7:10 http://www.biomedcentral.com/1472-684X/7/10
Page 2 of 10
(page number not for citation purposes)
life, Jordhoy et al [2] found that out of the 39 existing pal-
liative care assessment tools, 11 included original per-
formance status assessments, and only two of them, PPS
and Edmonton Functional Assessment Tool (EFAT) incor-
porated comprehensive performance status measures. PPS
is observer-rated and includes five domains (on a Scale of
0% to 100%, in increments of 10%) – Ambulation; Self-
care; Activity Level/Evidence of Disease; Intake and Level
of Consciousness (Additional file 1). It is adapted from
the Karnofsky Performance Scale [3].
A brief review of the literature showed only a dozen arti-
cles on PPS, including the original 1996 Anderson article
where its development was first reported. Only seven of
these articles are on the validity of PPS in prognostication
and its usefulness in the prediction of survival of palliative
care patients. Five of these articles are in peer-reviewed
journals (Morita [4] 1999; Virik [5] 2002; Harrold [6]
2005; Head [7] 2005; Lau [8] 2007), with the other two
being conference presentations and abstracts (Younis [9]
2003; Olajudin [10] 2004). Other documented areas
where PPS are used include disease progress monitoring
and care planning. In the Canadian Health Services
Research Foundation report by Dudgeon, on Collabora-
tive Care Plans [11], PPS was one of the assessment tools
recommended. In another article on advance planning
and palliative care in nursing homes in USA, Levy also
used PPS for prognostication and palliative care interven-
tions [12]. The "BC Palliative Care Benefit Program
(2001)" of British Columbia, Canada, contains a guide-
line for their Drug Benefit Program, stating that eligible
patients must be in the terminal stage of illness with an
entry point PPS of 50% level or below [1].
Downing et al [13] in their meta-analysis study of PPS,
found only Harrold [6] reported interrater reliability test
results for PPS in a pilot study with a small sample size (n
= 30). As PPS is becoming more widely used in palliative
care, and no formal study has been done on its inter- and
intrarater reliability and validity, it is important for clini-
cians to have solid evidence that PPS % level scores can be
repeated consistently and also accurately reflect the func-
tional status of the patients assessed.
This study has two objectives: (1) to examine the inter-
and intrarater reliability of the PPS by clinicians, (2) to
examine the validity of the PPS by content validation,
questioning clinicians on its purpose and usefulness.
Methods
This study obtained ethics approval for human participant
research, by the Human Research Ethics Board, University
of Victoria, BC (Protocol Number 07-05-385b), and has
met the standards of research design, and the protection
of rights and security of data.
Reliability study
The reliability study was designed as a web-based scenar-
ios study using a secure website, initially with 22 simu-
lated palliative care patient case histories created from
actual clinical settings (see Additional file 2 for a sample
case). Because the time required to evaluate all 22 cases
was too long, we randomly divided the cases into two
groups: 1 and 2, with 11 cases in each. When a participant
first registered, a random number, either 1 or 2 was gener-
ated by computer program, and the participant was
assigned to the corresponding group. When a participant
logged onto the website, he/she was presented with the
PPS and its instructions of use. The cases were presented
in a random order, so that no two participants in the same
group read the cases in the same sequence. The participant
was asked to review the history of each case, assign a PPS
% level and go on to the next case, until all 11 cases were
completed. This was Time-1 of the reliability study. Two
weeks later, each participant was invited back to repeat the
test in the same way, with the same 11 cases and the same
sequence of presentation. This was Time-2 of the reliabil-
ity study.
Case Development
The cases were in narrative format. Palliative care clini-
cians from hospices, in-hospital consultation services and
palliative out-patient clinics provided us with their patient
case histories. Cases were developed using the material
obtained, modifying them somewhat to ensure anonym-
ity, with the intention of covering all scenarios of the dif-
ferent PPS % levels, from PPS 10% to PPS 100%. A panel
of palliative care experts, three physicians and three nurses
(Case Development Experts), reviewed all of the cases at a
face to face meeting. First each case was scored by the
experts individually, then the score results were compared
and the differences in PPS % levels (if any) were dis-
cussed, and with consensus, the narration/wordings of
each case were adjusted to be consistent with a given PPS
% level. There were 22 cases in total.
Participant Recruitment
Participants of the reliability study were recruited through
a two step process. An email with an attached invitation to
participate, was sent to the administrators and senior cli-
nicians of various palliative care institutions across Can-
ada and the U.S.A. (Victoria, Vancouver, Calgary,
Edmonton, Toronto, Hamilton, Kingston, Montreal,
Newfoundland, Nova Scotia and North Carolina),
requesting that they forward the invitation to their mem-
bers and colleagues. This invitation provided detailed
information about the mechanics of the web-based study,
the researchers involved, the anonymyzed format of the
data obtained, participants' confidentiality, the time
required for participants to complete the study and the
steps in giving consent, and/or withdrawing from theBMC Palliative Care 2008, 7:10 http://www.biomedcentral.com/1472-684X/7/10
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study. Upon receiving the forwarded invitation, clinicians
(palliative care physicians and nurses) responded by
returning an 'acceptance to participate' email to the
researchers, agreeing to participate in the study. A user-
name and password were created for each participant and
together with the URL of the secure website, were sent to
them by email.
Validity study
The validity study was performed through content valida-
tion interviews with palliative care experts, discussing
their experiences using PPS. An email 'invitation to partic-
ipate' was sent to clinicians (both physicians and nurses),
who were experts in using PPS in their palliative care prac-
tice. Potential participants' names were obtained from
suggestions by one of the authors of this study. Included
in the invitation email was a list of five questions that
would be discussed in a telephone interview. The ques-
tions were based on five themes: PPS as a clinical assess-
ment tool, areas of usefulness of PPS, how the PPS scores
affected clinicians' decision making in patient manage-
ment, the problems in using PPS, and the adequacy of PPS
instruction. Experts were also asked about the number of
years they have been using PPS. The questions were
approved by the authors of the study before they were sent
out to the potential participants. For those who returned
an acceptance email, arrangements were made for appro-
priate interview schedules. The experts recruited were
from across Canada and the U.S.A. (Victoria, Vancouver,
Edmonton, Toronto, Kingston, and Newfoundland and
North Carolina). Each interview took approximately
20–30 minutes, notes were taken and the interviews were
audio-recorded for cross-referencing. One author col-
lected all the interview results and all opinion and sugges-
tions were sorted under the five themes. These were
presented, discussed and content-analyzed by all authors
in a meeting, questions were raised and referred back to
the recordings for clarification.
Analytical Methods
The data obtained from the reliability portion of the study
was analyzed using SPSS version 15.0 and R version 2.5
software. The reliability of PPS was evaluated using the
single rating intraclass correlation coefficient (ICC) for
absolute agreement and for consistency using two-way
random-effects models. Single rating measures were used
because our interest was in ICC measures for individual
participants rather than averages of independent meas-
ures. The ICCs were obtained for each time period.
Participant reliability was evaluated using Cohen's kappa,
which is a chance-corrected measure of agreement
between two participants. It ranges from 0 (chance agree-
ment) to 1 (perfect agreement), and generally a kappa >
0.7 is considered satisfactory. An interpretation by Landis
and Koch [14] divided kappa into six categories: < 0 (no
agreement), 0.0–0.20 (very low agreement), 0.21–0.40
(low agreement), 0.41–0.60 (moderate agreement),
0.61–0.80 (full agreement) and 0.81–1.00 (almost perfect
agreement).
We looked at the results of individual cases, using box-
plots. The top and bottom of the box represent the 75th
and 25th percentiles respectively, a horizontal line across
the box identifies the median, and the hinges on the top
or bottom are the highest and lowest values excluding
outliers. Outliers are depicted with circles, and are defined
as values that extend from 1.5 to 3 box lengths below the
25th percentile or above the 75th percentile. We also com-
pared participants' scores to the intended PPS % levels
agreed upon by the Case Development Experts.
Content validity is based on the extent to which a meas-
urement adequately and comprehensively reflects the spe-
cific intended domain of content, and it employs a
reference standard. In our study, we questioned the
experts regarding the usefulness and problems of PPS. The
reference standard we used was the actual experience of
the experts in the domain of palliative care. During our
telephone interviews with palliative care experts, notes
were taken and the discussions were audio-recorded. Con-
tent analysis of the interviews was based on the notes
taken, cross referenced with the audio-recording when
required and the results were grouped into five themes for
reporting.
Results
Reliability study
Descriptive Analysis
A total of 62 emails were sent to administrators and senior
clinicians of palliative care institutions, requesting them
to forward our "Invitation to Participate" letter to their
colleagues and members. We do not have a record of
which administrators and senior clinicians actually for-
warded our letter, but we did have a total of 73 individuals
who returned a 'consent to participate' email. Out of these
participants, 65 completed Time-1, and among them, 53
also completed Time-2. Only scores of participants who
completed both Time-1 and Time-2 were included in this
study.
The participants were randomly assigned to Group 1 or
Group 2, each with 11 cases. There were 25 participants in
Group 1 and 28 in Group 2. By design, the range of PPS %
levels of all the 22 cases (both Group 1 and Group 2) cov-
ered the entire spectrum of values, from PPS 10% to PPS
100%. Because the 22 cases were randomly allocated to
either Group 1 or Group 2 (each with 11 cases) when the
study was first set up, Group 1 ended up with no represen-BMC Palliative Care 2008, 7:10 http://www.biomedcentral.com/1472-684X/7/10
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tation at PPS 20% and PPS 80% and Group 2 with no PPS
40%, 70% and 100%.
Figures 1, 2, 3 and 4 are boxplots of the PPS % scores by
case for the two time periods for both Group 1 and Group
2. The variation is quite small for most cases, within 0–2
PPS % levels, indicating consistency in scoring. Outliers
were present in about half of the cases, not necessarily at
the same PPS % levels or with the same case for both
Time-1 and Time-2. The second row of numbers on the x-
axis of the boxplots represents the intended PPS % level of
each case as determined by the Case Development
Experts. In each Figure, for eight out of the 11 cases, the
intended PPS % levels were the same as the medians of the
boxplots and for the remaining three cases, in all but one
Figure, the intended PPS % levels fall within the 75th and
25th percentiles of each boxplot. Over all of the participant
and case scores, 67.6% were the same as those intended
by the Case Development Experts. Thus there is strong
agreement between the Case Development Experts and
the participants.
Reliability Analysis
The reliability of PPS was calculated using ICC for abso-
lute agreement and for consistency using two-way ran-
dom-effects models. ICC measures the proportion of
variance in the measurements attributable to the cases.
Larger values, near 1, indicate that most of the variation in
the measurements is due to the differences in the cases,
rather than to variability between participants. Values
were obtained for each time period for the two groups.
Absolute agreement measures take into account partici-
pant variability, while measures of consistency do not.
Table 1 summarizes the reliability results. The consistency
and absolute agreement values are very similar and high,
around 0.96, indicating good agreement among partici-
pants.
Participants (raters) Reliability
Table 2 shows a cross tabulation of PPS % levels at Time-
1 and Time-2, Group 1 and 2 combined. The x-axis repre-
sents PPS % levels of participants at Time-2, and the y-axis
represents PPS % levels of participants done at Time-1.
Boxplot Group 1 Time-1 Figure 1
Boxplot Group 1 Time-1. The Y-axis represents the participants' PPS % levels, the top line X-axis shows the individual case 
number, and the 2nd line X-axis gives the intended PPS % levels as determined by the Case Development Experts.
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The least amount of deviation occurred at the two ends of
the PPS % levels, i.e. PPS 10% and PPS 100%, suggesting
that it is easier to score the same value (PPS 10% and PPS
100%) in both Time-1 and Time-2, when patients were
either healthy or very sick. Overall 74.4% of the scores
were on the diagonal, indicating most participants scored
with the same values in both Time-1 and Time-2.
Cohen's kappa
Table 3 lists the summary statistics for Cohen's kappa, cal-
culated over all of the participants, for Time 1 and Time 2.
Group 1 has a mean kappa of 0.67 and Group 2 has a
mean kappa of 0.71, indicating satisfactory results among
participants.
Validity study
In this study, we conducted content validation through
expert opinions. The 15 experts interviewed included
both physicians and nurses working in the field of pallia-
tive care as in-hospice clinicians, members of palliative
care home teams, hospital palliative consultants, physi-
cians of palliative out-patient clinics and physicians at
cancer institutes. They are from across Canada and U.S.A.
(British Columbia, Alberta, Ontario, Newfoundland and
North Carolina). All of them have used PPS for more than
two years; and one expert has used it since it was first
introduced over ten years ago.
The interviews were conducted, content analyzed and
grouped into five themes. The experts' opinions were
summarized as follows.
i. PPS as a clinical assessment tool
The experts agreed that PPS is a valuable tool in the clini-
cal assessment of all palliative care patients, not just end-
of-life patients. Some wanted to apply the usage of PPS to
other domains such as pediatric patients, acute in-hospital
patients or even suggested teaching patients and their
families how to use PPS, to assist them in making end of
life decisions. PPS is one of the standard assessment tools
in many experts' palliative care practices; although one
expert uses ECOG (Eastern Cooperative Oncology Group
Boxplot Group 1 Time-2 Figure 2
Boxplot Group 1 Time-2. The Y-axis represents the participants' PPS % levels, the top line X-axis shows the individual case 
number, and the 2nd line X-axis gives the intended PPS % levels as determined by the Case Development Experts.
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Performance Status) with his oncology patients and uses
PPS only with his other patients, other experts use PPS
with all their palliative care patients. One other expert
pointed out that PPS is helpful in tracking a disease trajec-
tory, especially when a patient's condition is deteriorat-
ing.
ii. Areas of usefulness of PPS
Areas of use are emphasized differently, depending on the
type of practice of the experts. Patients of hospital pallia-
tive consultants are in quicker transition, and by the time
they are consulted, patients are usually at the end-stage of
life. In these situations with PPS levels of 10%–20%, prog-
nostication is a more important issue than disease moni-
toring. For in-hospice clinicians, patient disease
monitoring during their end-of-life course in hospital, is
as important as prognostication. For hospital palliative
care administrators, patient care planning and hospital
resource allocation (e.g. hospital beds), become priorities.
A detailed description of patients in the various areas of
their palliative care program, using PPS as the indicator of
patients' state, can help in administrative planning. Palli-
ative care home nurses frequently use PPS to evaluate
which patients require home nursing care. PPS is a useful
tool for teaching residents to include patient function in
their assessment of whether a patient should be dis-
charged from hospital.
iii. How PPS scores affect clinicians' decision making in patient 
management
As one expert pointed out, PPS is valuable in placement,
but not in treatment decision making. Clinicians are
trained to base treatment decisions on patient symptoms.
On the other hand, PPS can assist family members in
making tough end-of-life decisions. PPS is also helpful in
decision in placement of patients, from active care to pal-
liative care.
iv. Problems using PPS
Problems raised by the experts can be categorized as: (1)
on PPS performance status (2) PPS % level scores (3) PPS
learning curve and (4) PPS as communication tool. Many
Boxplot Group 2 Time-1 Figure 3
Boxplot Group 2 Time-1. The Y-axis represents the participants' PPS % levels, the top line X-axis shows the individual case 
number, and the 2nd line X-axis gives the intended PPS % levels as determined by the Case Development Experts.
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experts felt that PPS should be left as is; however, two
experts thought some performance status indicators
needed to be further defined. For example, ambulation
should specify the length of time that a patient can sit in a
chair. The term "oral intake" should be redefined to
include other types of intake, for example, NG/PEG tube
feeding and supplements. The scoring of comatose
patients is unclear, and the meaning of "extensive disease"
is more difficult to define in cases of COPD or stroke.
Some experts found it more difficult to score at certain
PPS % levels. One expert asked what to do with PPS %
level scores that fell in between two levels and requested
finer grading of PPS % levels. One expert found it easier to
score with lower PPS % levels, and more difficult with
higher levels. Other experts found it troublesome to dis-
tinguish between certain PPS % levels, e.g. between PPS
30% and 40%, or between PPS 80% and 90%. In a tertiary
care setting, patients' PPS % level are usually above PPS
Table 1: PPS – ICC
Consistency Absolute Agreement
Group Time Period Intraclass Correlation 
(95%CI)
Intraclass Correlation 
(95%CI)
1 (n = 28) 1 .960 (.919, .987) .959 (.917, .986)
1 2 .963 (.926, .988) .964 (.927, .988)
2 (n = 25) 1 .959 (.917, .986) .951 (.901, .984)
2 2 .938 (.878, .979) .931 (.864, .977)
Reliability Results – Intraclass Correlations and their 95% Confidence Intervals
Boxplot Group 2 Time-2 Figure 4
Boxplot Group 2 Time-2. The Y-axis represents the participants' PPS % levels, the top line X-axis shows the individual case 
number, and the 2nd line X-axis gives the intended PPS % levels as determined by the Case Development Experts.
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60%, and those experts had less experience dealing with
lower PPS levels.
One expert commented that if PPS % levels were used in
disease trajectory monitoring, the trajectory shape, linear
or nonlinear could depend on how frequently PPS % level
was recorded. For example, a patient admitted with PPS
10%, may be at PPS 40% after treatment, then drop back
to 10% within a few days. If PPS % levels were only taken
at both ends of this time period, a linear graph would
result, with no change in PPS % level. But if the PPS % lev-
els were taken more frequently, then a curve would be
obtained.
One expert who used PPS only for his non-cancer patients
found that PPS had too many variables to remember, so
that he frequently referred back to the PPS table and
required PPS instructions while using the tool, while oth-
ers who used PPS regularly had no such problem.
Experts agreed the learning curve for PPS is somewhat
steep, but once it is used properly, PPS is a good commu-
nication tool and becomes a standard reference for pallia-
tive care workers to discuss patients' conditions among
themselves. One expert suggested, "Sometimes it is lazi-
ness that prevents palliative care workers from under-
standing how to use PPS."
v. Adequacy of PPS instruction
Some found the guideline was very useful but too long to
review and it was sometimes difficult to find detailed
information in the descriptions. One expert suggested
moving some of the instructions to the actual PPS table.
Another expert requested more case examples be
included.
Discussion
Reliability
PPS is an important clinical assessment tool in palliative
care, and its indicators are based on the performance sta-
tus of the patient. It has been used in prognostication, dis-
ease progress monitoring, in administration and health
care planning. It is reliable with ICC values for consistency
and absolute agreement around 0.96. From Table 2, the
Cross Tabulation of Time-1 and Time-2 Scores, the PPS %
levels are consistently scored the same over the two time
periods. When comparing the participants' PPS % levels
with the intended PPS % levels set by the Case Develop-
ment Experts, the agreement was very good; demonstrat-
ing that PPS can produce consistent results among users
and that PPS is a reliable tool.
Cohen's kappa was used to measure interrater reliability
of participants over time, with a mean kappa of 0.67 in
Group 1 and 0.71 in Group 2. Because there were only 11
cases evaluated by each participant, kappa values were
greatly influenced by any scores that were not the same
over the two time periods. With a larger number of cases,
we would expect greater test-retest reliability.
Table 3: Cohen's Kappa Statistics
mean median max min
Group 1
0.6680388 0.6379710 1.0000000 0.2735849
Group 2
0.7099952 0.6886792 1.0000000 0.3592233
Table 2: Cross Tabulation of Time-1 & Time-2 Scores
Time-1 Time-2
Level 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Total
10% 51 000000000 5 1
20% 5 57 1 1 1010000 7 5
30% 0 10 30 4000000 4 4
40% 0 0 4 65 910000 7 9
50% 0 0 0 16 30 30000 4 9
6 0 % 0001641 4201 5 5
7 0 % 000011 8 53 800 8 0
8 0 % 0000061 5 26 10 4 8
9 0 % 0000001534 34 3
1 0 0 % 00000000732 39
T o t a l 5 66 74 58 74 67 07 34 14 23 6 5 6 3
Time 1 vs Time 2 PPS % levels of all 22 cases.
The X-axis represents the Time 2 scores and Y-axis represents the Time 1 scores.
The values in the table represent the total number of scores at each PPS % level at Time 1 and Time 2.BMC Palliative Care 2008, 7:10 http://www.biomedcentral.com/1472-684X/7/10
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The boxplots of PPS scores demonstrated that outliers
were present. This phenomenon can be explained as a
built-in problem of the study design. Participants based
the PPS scores on the text narration of the case history. For
some cases, a performance status could be determined
from only a few words about a patient's condition. If
those words or description were overlooked, a different
level would be assigned. In an actual clinical setting, each
performance evaluation is based on the observation of the
patient, and if the clinician is unsure of the patient's func-
tion, he/she can re-examine a patient repeatedly to arrive
at a satisfactory PPS % level. This minimizes the chance of
outliers. Also PPS is usually used as a communicative tool,
where palliative care workers can come to consensus of a
PPS % level, as the basis for discussion about an individ-
ual patient.
Validity
The validity study was based on content validation using
interviews with palliative care experts, on different aspects
of PPS usage. All of the experts agreed that PPS is a valua-
ble clinical assessment tool in palliative care and many of
them have already incorporated PPS as standard in their
practice. Most did not feel a need to further modify PPS,
with the exception of two experts who suggested fine tun-
ing to better define some performance status indicators,
specifically oral intake and mobility.
Difficulty can be found in two areas: scoring a PPS % level
and in learning how to use PPS. Some experts found occa-
sional uncertainty in differentiating between PPS % levels
of 30% and 40%, and also between PPS % levels 80% and
90%. Others were not sure about the 'in-between' values
of two adjacent PPS % levels, although it is strongly
emphasized in the PPS instruction manual, to utilize the
'best fit' method in determining the best horizontal PPS %
level. Some PPS users may not read the instructions care-
fully enough to extract this intent.
Does this mean the PPS scale should be sub-divided into
finer grading? There will always be 'in-between' values; no
matter how finely tuned the grading system is. The bal-
ance between ease of use with fewer scores and complexity
of using more line items was weighed in favour of the
former. Trying to remember 22 lines versus 11 would
reduce the utility, and thus the 'best fit' remains the
approved standard. Although the learning curve for PPS is
initially difficult for some, its ease of use (including differ-
entiating between certain PPS % levels) comes with prac-
tice and experience.
The use of PPS in prognostication has been studied by a
few researchers [6-8] over the past ten years. PPS is also
used in decision making in hospital administration plan-
ning and resource allocation and PPS is used as a qualifier
for admission into a drug benefit program [15] and home
nursing care programs. It is also useful in disease monitor-
ing, clinical teaching and research. Such multiple pur-
poses strengthen its validation.
Among hospital and hospice palliative care workers, PPS
is a good communication tool for discussing patients'
condition. For a given PPS % level, everyone will know
what condition the patient is in, and has a clear concept
of the performance statuses that come with that particular
PPS % level. PPS simplifies and enhances communica-
tion.
In summary, the palliative care experts agreed that PPS is
valuable in clinical assessment, and has been integrated
into their standard of practice. Although a few raised the
question of modifying the performance status measures,
most felt PPS should be left as is. Although it requires time
to learn initially, but once mastered, it is very valuable in
communication.
Conclusion
This article has described the reliability testing and valid-
ity study of PPS, a clinical performance assessment tool
used in palliative care patient management. The reliability
testing showed PPS is a reliable tool. Our validity study
was based on the content validation of palliative care
experts, and they all agreed that PPS is valuable in the clin-
ical assessment of palliative care patients.
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